Home Wellness Insights

21Jul

Tirzepatide Statistics 2026: Mounjaro & Zepbound Data, Clinical Outcomes & Market Trends | GoalBMI

Tirzepatide Statistics 2026: Mounjaro & Zepbound Data, Clinical Outcomes & Market Trends | GoalBMI Wellness

📊 Statistics Report — Updated July 2026

Tirzepatide Statistics 2026: Mounjaro & Zepbound Data, Clinical Outcomes & Market Trends

The most comprehensive tirzepatide statistics resource for 2026. Covers Mounjaro and Zepbound global sales, SURMOUNT trial weight loss outcomes, how tirzepatide compares to semaglutide, market growth projections, pricing, and what the latest research shows about the world’s best-selling drug.

📅 Last Updated: July 2026 ⏱ 12 min read ✔ Physician Reviewed 📚 13 Cited Sources

$0B

Tirzepatide combined 2025 global sales — world’s #1 drug

Eli Lilly Annual Report, 2026

Average weight loss at highest dose — SURMOUNT-1

NEJM SURMOUNT-1, 2022

Of patients lost 20%+ body weight — SURMOUNT-1

Jastreboff et al., NEJM 2022

Zepbound share of new US obesity prescriptions (Q3 2025)

Eli Lilly Q3 2025 Report

Tirzepatide — sold as Mounjaro for type 2 diabetes and Zepbound for weight management — became the world’s best-selling drug in 2025 with combined global sales of $36.5 billion. Its dual mechanism targeting both GLP-1 and GIP receptors produces weight loss outcomes that consistently outperform every other approved medication. This page compiles the most current statistics on clinical outcomes, sales data, market trends, and real-world usage available in 2026.

Section 01

What Is Tirzepatide — Brand Names & Key Facts

Tirzepatide is a once-weekly injectable medication developed by Eli Lilly that activates both GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors simultaneously. It is the only approved dual GLP-1/GIP receptor agonist in the world — and this dual mechanism is what drives its superior weight loss outcomes compared to GLP-1-only medications like semaglutide.

Brand Name	Approved For	Doses Available	FDA Approval	2025 Global Sales
Mounjaro®	Type 2 diabetes management	2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg weekly	May 2022	$22.7 billion (+67.1%)
Zepbound®	Chronic weight management (obesity)	2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg weekly	November 2023	$13.8 billion (+188.7%)
Combined	Diabetes + obesity (same active ingredient)	Same formulation, different branding	—	$36.5 billion (#1 globally)

2025 milestone: Combined Mounjaro and Zepbound sales of $36.5 billion made tirzepatide the world’s best-selling drug in 2025 — surpassing Novo Nordisk’s combined semaglutide portfolio ($33 billion) and Merck’s Keytruda ($31.7 billion). Tirzepatide accounted for 56% of Eli Lilly’s total revenue in 2025. (Source: FiercePharma, February 2026)

Section 02

Tirzepatide Sales Data 2022–2026

Tirzepatide’s revenue growth trajectory is unprecedented in pharmaceutical history. From its 2022 launch to its 2025 status as the world’s best-selling drug, the growth rate has consistently outpaced every analyst projection.

$36.5B

Combined Mounjaro + Zepbound 2025 global sales — world #1 drug

$10.1B

Single quarter sales — Q3 2025 alone, beating Keytruda ($8.1B)

+185%

Zepbound year-over-year sales growth in Q3 2025

Mounjaro vs Zepbound Annual Sales Growth 2022–2025 (USD Billions)

Source: Eli Lilly annual and quarterly financial reports. Zepbound growing faster despite launching 18 months after Mounjaro.

📈

Zepbound: 2,684% Growth in Its First Full Year on Market

Zepbound launched in November 2023 and achieved 2,684% year-over-year revenue growth in its first full year (2024) — the fastest launch in obesity drug history. By Q3 2025, Zepbound held 71% of all new US obesity prescriptions, having overtaken semaglutide (Wegovy) as the dominant choice for weight management. (Source: Drug Discovery Trends, November 2025)

💊

Market Projected to Reach $115.9 Billion by 2030

The global tirzepatide market is projected to grow from $482.5 million in 2022 to $115.9 billion by 2030 — a compound annual growth rate (CAGR) of 40.17%. This represents one of the fastest CAGR rates ever recorded for a pharmaceutical product and reflects the massive unmet need in obesity treatment globally. (Source: Coherent Market Insights, 2026)

Global Tirzepatide Market Size — Historical & Projected (USD Billions)

Source: Coherent Market Insights, 2026. CAGR of 40.17% — one of the fastest in pharmaceutical history.

Section 03

Tirzepatide Clinical Trial Outcomes — SURMOUNT Trials

The SURMOUNT clinical trial program produced the most impressive weight loss data ever recorded for a non-surgical pharmacological intervention. Across four major trials, tirzepatide consistently delivered outcomes that exceed every previously available treatment.

Average Weight Loss by SURMOUNT Trial — Tirzepatide vs Placebo (%)

Sources: NEJM SURMOUNT-1 (2022), SURMOUNT-2 (2023), SURMOUNT-4 (2023). All at 72–88 weeks.

Trial	Population	Tirzepatide	Placebo	Key Finding
SURMOUNT-1	Adults with obesity (no T2D) — 2,539 patients	−22.5% (15mg)	−2.5%	Highest dose: 50%+ lost 20% body weight
SURMOUNT-2	Adults with obesity + type 2 diabetes	−15.7% (15mg)	−3.3%	Significant despite diabetes reducing response
SURMOUNT-3	Obesity + intensive lifestyle intervention	−26.6%	−3.0%	Highest weight loss ever in a drug trial
SURMOUNT-4	Continued vs discontinued treatment	−21% maintained	+14% regained	Stopping leads to significant regain in 1 year
SURPASS-2	T2D — tirzepatide vs semaglutide head-to-head	−15%	Sema: −8%	Tirzepatide nearly double the weight loss of semaglutide

Historic result from SURMOUNT-3: When tirzepatide was combined with intensive lifestyle intervention, patients achieved an average of 26.6% body weight loss — the highest average weight loss ever recorded in a controlled clinical drug trial. More than 40% of participants achieved at least 30% body weight loss. This trial established tirzepatide-plus-lifestyle as the most effective non-surgical weight loss approach available.

22.5%

Average weight loss at 15mg — SURMOUNT-1 (no T2D patients)

>50%

Of SURMOUNT-1 patients who lost 20% or more of body weight

26.6%

Average weight loss with intensive lifestyle — SURMOUNT-3 (all-time record)

Weight Loss Progress Over Time — SURMOUNT-1

Body Weight Change — Tirzepatide 15mg vs Placebo Over 72 Weeks (SURMOUNT-1 %)

Source: Jastreboff A.M. et al., NEJM 2022. Weight loss is progressive, dose-dependent, and sustained through week 72.

📖 Related at GoalBMI Wellness

Tirzepatide Programs — GoalBMI Wellness Tirzepatide Side Effects: Complete Patient Guide Rebound Weight Gain After Stopping Tirzepatide

Section 04

Tirzepatide vs Semaglutide — Head-to-Head Data

The most searched question about tirzepatide is how it compares to semaglutide (Ozempic/Wegovy). The clinical and real-world data in 2026 consistently shows tirzepatide delivering superior weight loss outcomes — though both medications are highly effective.

Tirzepatide vs Semaglutide — Average Weight Loss Comparison (%)

Sources: SURMOUNT-1 (tirzepatide, NEJM 2022) vs STEP-1 (semaglutide, NEJM 2021). Different trials — use as directional comparison.

Metric	Tirzepatide (Zepbound®)	Semaglutide (Wegovy®)	Advantage
Average weight loss (highest dose)	22.5%	15.0%	Tirzepatide +7.5%
Patients achieving 20%+ loss	>50%	~31%	Tirzepatide wins
More weight loss than semaglutide on avg	~50% more weight loss on average		Tirzepatide wins
Likelihood of 15%+ weight loss vs Ozempic	3.2× more likely with Mounjaro vs Ozempic		Tirzepatide wins
Cardiovascular trial	SURPASS-CVOT (positive)	SELECT (20% CV reduction)	Both proven
Oral formulation available	Not yet (in development)	Yes — Wegovy pill launched Jan 2026	Semaglutide leads
FDA boxed warning	Thyroid C-cell tumors	Thyroid C-cell tumors	Same for both
US obesity prescription share (Q3 2025)	71%	29%	Tirzepatide leads

Key finding from SURPASS-2 (head-to-head trial): In the only direct head-to-head trial, tirzepatide produced nearly double the weight loss of semaglutide — 15% vs 8% in T2D patients. Patients were also 3.2 times more likely to achieve clinically significant 15% weight loss with Mounjaro than with Ozempic. (Source: The World Data, April 2026)

📖 Full Comparison Guide

Semaglutide vs Tirzepatide — Complete Comparison Guide GLP-1 Weight Loss Statistics 2026 Semaglutide Statistics 2026

Section 05

Tirzepatide — Health Benefits Beyond Weight Loss

Like semaglutide, the clinical evidence for tirzepatide extends well beyond weight loss. The 2026 research landscape shows meaningful benefits across multiple chronic conditions closely linked to obesity.

↓ T2D

Significant HbA1c reduction — primary diabetes indication

↓ BP

Blood pressure improvements observed across SURMOUNT trials

↓ LDL

Cholesterol improvements in patients across multiple trials

↓ SAS

FDA approved for sleep apnea treatment — June 2024

😴

First Drug Approved for Obesity-Related Sleep Apnea — June 2024

In June 2024, the FDA approved Zepbound (tirzepatide) for treating moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity — making it the first drug ever approved for this indication. Clinical trials showed tirzepatide reduced sleep apnea events by up to 62.8% in patients with obesity. Approximately 30 million Americans have sleep apnea, and more than 80% of cases are obesity-related. (Source: FDA, 2024)

❤️

SURMOUNT-MMO Cardiovascular Trial — Results Pending 2026

The SURMOUNT-MMO trial — tirzepatide’s equivalent of semaglutide’s SELECT trial — is enrolling adults with obesity and established cardiovascular disease. Preliminary data presented in 2025 showed positive trends. Final results are expected in late 2026 and could significantly expand tirzepatide’s FDA-approved cardiovascular indication, mirroring the SELECT breakthrough for semaglutide.

🫀

Heart Failure with Preserved Ejection Fraction (HFpEF)

Tirzepatide has shown significant improvements in patients with heart failure with preserved ejection fraction (HFpEF) and obesity — a condition that affects millions of Americans and has very limited treatment options. A 2024 trial showed tirzepatide reduced hospitalization for heart failure and improved quality of life scores significantly. This indication is currently under FDA review.

Health Improvement Progress — SURMOUNT Trial Findings

Patients achieving 22.5% average weight loss (15mg, SURMOUNT-1)22.5%

Patients losing 20%+ body weight (SURMOUNT-1)>50%

Sleep apnea events reduced (OSA trial)62.8%

More weight loss vs semaglutide on average~50%

Zepbound share of new US obesity prescriptions (Q3 2025)71%

Section 06

Who Is Using Tirzepatide in 2026?

As of 2025, approximately 11 million unique patients were using a GLP-1 medication across all indications — a number growing rapidly. Tirzepatide’s share of this population has grown dramatically since Zepbound launched in November 2023.

11M

Unique US patients using a GLP-1 drug as of Q2 2025 (across all medications)

71%

Zepbound share of new US obesity prescriptions by end of Q3 2025

35%

Zepbound prescriptions that were cash-pay in Q2 2025 — bypassing insurance

Tirzepatide Prescription Volume Growth — Quarterly (Indexed, 2023 Q4 = 100)

Source: IQVIA / Eli Lilly quarterly reports. Illustrates the explosive adoption trajectory since Zepbound launch.

🛒

Walmart Now Offers Zepbound at LillyDirect Prices

In 2025, Walmart began offering Zepbound at LillyDirect prices starting at $349 per month for the lowest dose — making tirzepatide accessible through one of the most widely distributed retail networks in the US. This partnership dramatically expanded access for patients in rural and underserved areas, and approximately 35% of Zepbound prescriptions in Q2 2025 were cash-pay, bypassing traditional pharmacy benefit manager gatekeeping entirely. (Source: Drug Discovery Trends, 2025)

🌍

Tirzepatide Expanding Globally — Japan Launch March 2026

On March 19, 2026, Eli Lilly and Mitsubishi Tanabe Pharma announced the availability of Zepbound in Japan — a market with approximately 28 million people living with obesity. The Asia Pacific region is expected to exhibit the fastest tirzepatide market growth globally, with a projected 25.7% market share by the end of the decade. (Source: Coherent Market Insights, 2026)

Real Patient Outcomes

Before & After — Tirzepatide & Semaglutide Results at GoalBMI Wellness

These outcomes reflect real patients from physician-supervised GLP-1 programs at GoalBMI Wellness. Results are consistent with what the SURMOUNT and STEP clinical trials demonstrated under supervised conditions with physician oversight and ongoing monitoring.

Before and after tirzepatide and semaglutide weight loss results — GoalBMI Wellness physician-supervised telehealth programs

Results disclaimer: Individual results may vary. Photos represent real patients from physician-supervised GoalBMI Wellness programs shared with patient consent. Results depend on individual health factors, program adherence, and medical evaluation. All medications require a licensed provider evaluation and prescription.

Clinical context: SURMOUNT-1 showed tirzepatide produced an average of 22.5% body weight loss at 72 weeks at the highest dose. STEP-1 showed semaglutide produced 15% at 68 weeks. GoalBMI Wellness telehealth programs are built around the same physician-supervised clinical protocols — delivered entirely online for eligible patients across New York, New Jersey, Pennsylvania, and Connecticut.

Tirzepatide Programs → Semaglutide Programs →

Transparent Pricing

Tirzepatide Program Pricing at GoalBMI Wellness

Cost is one of the most frequently asked questions about tirzepatide. The pricing landscape has changed significantly in 2025–2026 with government pricing negotiations, new access programs, and manufacturer savings cards making tirzepatide more accessible than ever before.

GoalBMI Wellness tirzepatide program pricing — self-pay options and insurance coverage for Mounjaro and Zepbound

💰

2026 Tirzepatide Pricing — Key Numbers

TrumpRx program: Zepbound and Mounjaro capped at $245/month (announced November 2025). Walmart/LillyDirect: Starting at $349/month for the lowest dose. Manufacturer savings card: Eligible commercially insured patients may pay as little as $25/month. Compounded tirzepatide: Available through licensed 503A pharmacies at potentially lower costs when clinically appropriate. Visit our program pricing page for current GoalBMI Wellness rates.

View Program Pricing → Verify Insurance →

Section 07

Tirzepatide Timeline — Key Milestones 2022–2026

May 2022

Mounjaro FDA Approved — Tirzepatide Enters the Market

FDA approves Mounjaro (tirzepatide) for type 2 diabetes management — the first dual GLP-1/GIP receptor agonist ever approved. The SURPASS trials had shown remarkable HbA1c reductions and unexpected weight loss benefits. Eli Lilly’s stock begins a multi-year climb.

May 2022

SURMOUNT-1 Submitted — 22.5% Weight Loss Data Shocks the Field

The SURMOUNT-1 trial results submitted to NEJM show tirzepatide produces up to 22.5% average body weight loss at 72 weeks — significantly higher than semaglutide’s 15% in comparable trials. The obesity medicine community takes notice of tirzepatide’s potential as a weight loss drug.

June 2022

SURMOUNT-1 Published in NEJM

Publication of SURMOUNT-1 data in the New England Journal of Medicine — 2,539 patients, up to 22.5% weight loss at highest dose, more than 50% of patients losing 20%+ of body weight. Described as a landmark moment in obesity pharmacotherapy.

November 2023

Zepbound FDA Approved for Weight Management

FDA approves Zepbound (tirzepatide 2.5mg–15mg) for chronic weight management in adults with obesity — the most effective obesity drug ever approved at the time. The approval triggers unprecedented demand and begins the Zepbound vs Wegovy competition for obesity market leadership.

June 2024

Zepbound Approved for Sleep Apnea — First Drug for OSA

FDA approves Zepbound for treating moderate-to-severe obstructive sleep apnea in adults with obesity — the first drug ever approved for this indication. Clinical trials showed up to 62.8% reduction in sleep apnea events. This opens a new patient population estimated at 30 million Americans.

Q3 2025

Tirzepatide Breaks $10 Billion in a Single Quarter

Mounjaro ($6.5B) + Zepbound ($3.6B) = $10.1 billion in Q3 2025 alone — outpacing Keytruda ($8.1B), Ozempic ($5.7B), and every other drug in a single quarter. Zepbound holds 71% of new US obesity prescriptions. Eli Lilly surpasses Novo Nordisk as the most valuable healthcare company in Europe and North America.

Full Year 2025

Tirzepatide Becomes World’s Best-Selling Drug — $36.5 Billion

Combined Mounjaro + Zepbound sales of $36.5 billion make tirzepatide the world’s best-selling drug in 2025 — surpassing semaglutide ($33B), Keytruda ($31.7B), and every other medication globally. Tirzepatide accounts for 56% of Eli Lilly’s total revenue. Eli Lilly stock is up 180% since Mounjaro’s 2022 approval.

2026

Global Expansion, TrumpRx Pricing, SURMOUNT-MMO Results Pending

Zepbound launches in Japan (March 2026), expanding tirzepatide’s global footprint. TrumpRx pricing caps Zepbound and Mounjaro at $245/month in the US. SURMOUNT-MMO cardiovascular trial results expected in late 2026. Market projected to reach $115.9 billion by 2030 with CAGR of 40.17%.

Section 08

Frequently Asked Questions

Mounjaro and Zepbound contain the same active ingredient — tirzepatide — but are approved for different indications. Mounjaro (approved May 2022) is FDA-approved for type 2 diabetes management. Zepbound (approved November 2023) is FDA-approved specifically for chronic weight management in adults with obesity or weight-related health conditions. They are the same medication at the same doses, with different branding and covered under different insurance categories.

According to the SURMOUNT-1 clinical trial, patients using tirzepatide 15mg (the highest dose) lost an average of 22.5% of body weight over 72 weeks. More than 50% of participants lost 20% or more of their body weight. In SURMOUNT-3, when combined with intensive lifestyle intervention, average weight loss reached 26.6% — the highest ever recorded for a drug trial. Individual results vary based on dose, adherence, diet, and health history.

Clinical trial data consistently shows tirzepatide produces greater average weight loss than semaglutide — approximately 50% more weight loss on average. Patients are 3.2 times more likely to achieve 15% weight loss with Mounjaro than Ozempic (World Data, 2026). However, both are highly effective medications. Semaglutide has a longer track record, a cardiovascular benefit proven in the SELECT trial, and now an oral formulation (Wegovy pill). The right choice depends on your individual health history, goals, and what your provider recommends. Read our full comparison: semaglutide vs tirzepatide guide.

Several pricing options exist in 2026: TrumpRx program: $245/month for Zepbound and Mounjaro (announced November 2025). Walmart/LillyDirect: Starting at $349/month for the lowest dose. Eli Lilly savings card: Eligible commercially insured patients may pay as low as $25/month. Compounded tirzepatide: May be available at lower costs through licensed 503A pharmacies when appropriate. GoalBMI Wellness offers insurance verification and transparent self-pay pricing. Visit our pricing page for current program costs.

Beyond type 2 diabetes (Mounjaro) and weight management (Zepbound), tirzepatide has been approved or is under investigation for: Obstructive sleep apnea (FDA approved June 2024 — first drug for this indication); heart failure with preserved ejection fraction (HFpEF) (under FDA review); cardiovascular risk reduction (SURMOUNT-MMO trial results expected 2026); and non-alcoholic steatohepatitis (NASH/MASLD) (liver disease). The breadth of tirzepatide’s clinical benefits continues to expand as trial results emerge.

Yes. GoalBMI Wellness provides physician-supervised tirzepatide programs for eligible patients in New York, New Jersey, Pennsylvania, and Connecticut through our telehealth platform. When clinically appropriate, providers may prescribe tirzepatide as Zepbound® or Mounjaro®. Compounded tirzepatide may also be available through licensed 503A pharmacies. All consultations, prescriptions, and follow-up care are conducted entirely online — no in-person office visits required. Visit wellness.goalbmi.com/contacts/ to get started.

References

Sources & Medical References

1Jastreboff A.M., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM, 387(3), 205–216. doi.org/10.1056/NEJMoa2206038
2Aronne L.J., et al. (2023). Continued Treatment with Tirzepatide for Maintenance of Weight Reduction (SURMOUNT-4). JAMA, 331(1), 38–48. doi.org/10.1001/jama.2023.24945
3Frías J.P., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). NEJM, 385(6), 503–515. doi.org/10.1056/NEJMoa2107519
4FiercePharma (February 4, 2026). Even with pricing headwinds, Eli Lilly expects sales surge to continue in 2026. Mounjaro + Zepbound full year 2025 sales: $36.5 billion. fiercepharma.com
5Drug Discovery Trends (November 2025). Lilly set to lead pharma by revenue in 2026. Zepbound Q3 2025 data and US obesity prescription share. drugdiscoverytrends.com
6Coherent Market Insights (2026). Tirzepatide Market Trends, Share and Forecast 2026–2033. CAGR 40.17%, $115.9B by 2030. coherentmarketinsights.com
7The World Data (April 2026). Ozempic vs Mounjaro Statistics 2026: Market Share, Users & Facts. 3.2× more likely to achieve 15% weight loss. theworlddata.com
8Accio.com (2026). Tirzepatide Trends 2026: Market Growth & Innovation. Mounjaro Q3 2025 +109% YoY. accio.com
9Fella Health (April 2026). How Many People Are on Tirzepatide: Usage and Access Data. fellahealth.com
10U.S. Food and Drug Administration (2023). Zepbound (tirzepatide) prescribing information. accessdata.fda.gov
11U.S. Food and Drug Administration (2024). FDA approves Zepbound for obstructive sleep apnea. fda.gov
12Eli Lilly and Company (2025). Annual Report — Financial Results. Tirzepatide revenue, market share, global expansion data. investor.lilly.com
13NIH / NIDDK (2024). Prescription medications to treat overweight and obesity. niddk.nih.gov

Medically Reviewed by Karla K. Mioduchoski, FNP-BC

Board-Certified Family Nurse Practitioner — GoalBMI Wellness

Karla K. Mioduchoski, FNP-BC is a board-certified Family Nurse Practitioner providing physician-supervised medical weight loss, GLP-1 support, peptide therapy, and telehealth wellness care through GoalBMI Wellness. All statistical data in this article was reviewed for clinical accuracy in July 2026.

Medical Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice. Statistics are sourced from peer-reviewed studies, government agencies, and authoritative research organizations as cited above. GoalBMI Wellness provides physician-supervised telehealth programs for eligible patients in participating states. In a medical emergency, call 911.

Get Started

Book an appointment and take the first step toward better health.

Book Now

Related Weight Loss Programs